Enanta Pharmaceuticals CEO Jay Luly Unloads 5,800 Shares (ENTA)
Enanta Pharmaceuticals (NASDAQ:ENTA) CEO Jay Luly unloaded 5,800 shares of the company’s stock on the open market in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $28.05, for a total transaction of $162,690.00. Following the transaction, the chief executive officer now directly owns 324,019 shares in the company, valued at approximately $9,088,733. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) traded up 2.05% during mid-day trading on Friday, hitting $28.86. The stock had a trading volume of 114,117 shares. Enanta Pharmaceuticals has a 52-week low of $14.31 and a 52-week high of $38.48. The stock’s 50-day moving average is $27.93 and its 200-day moving average is $21.43. The company’s market cap is $518.4 million.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, November 25th. The company reported ($0.25) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.29) by $0.04. The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $1.00 million.
A number of research firms have recently commented on ENTA. Analysts at Zacks downgraded shares of Enanta Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday. They now have a $33.30 price target on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Enanta Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $31.15.
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.